Should You Buy Zevra Therapeutics, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Zevra Therapeutics, Inc. (ZVRA) carries a solid Quality of Company rating of 6.5/10. Trading at $11.65, our multi-model framework evaluates whether the company's financial profile offers a favorable risk-reward setup.
The short answer: 2 of 6 CirclFi valuation models project upside for Zevra Therapeutics, Inc. (ZVRA) at $11.65 — the model consensus leans bearish, with a Quality Score of 6.5/10 and Value-Trap risk of 36/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Zevra Therapeutics, Inc. (ZVRA) in 2026?
What Is the Bull Case vs the Bear Case for Zevra Therapeutics, Inc. (ZVRA)?
| Bull case — $13.47 target (+15.6%) | Bear case — $0.97 target (-91.7%) |
|---|---|
| According to the CirclFi Deep Alpha Valuation Engine, the RCMH-DCF model targets a fair value of $13.47 (+15.6%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | According to the CirclFi Deep Alpha Valuation Engine, the Bayesian DCF model sees the stock as overvalued with a fair value of $0.97 (-91.7%), suggesting that the market price embeds overly optimistic growth assumptions. |
| Industry tailwind: partnership and licensing deals could provide meaningful support for Zevra Therapeutics, Inc.'s revenue and margin trajectory in the Biotechnology space. | According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +107.3% spread between the most bullish and bearish models, signaling elevated analytical uncertainty. |
| Industry headwind: binary clinical trial outcomes represents a meaningful risk for Zevra Therapeutics, Inc. and its Biotechnology peers. |
How Does ZVRA Compare to Its Biotechnology Peers?
Valuation data pages: ZEOX · VIR · WVE · NTRB · ACRS · TVTX · MANE · CBIO · BCLI · EXEL · INCY
Which Other Stocks Score Like ZVRA on Quality?
Closest companies to ZVRA’s Quality of Company score of 6.5/10, across all industries.
Which Biotechnology Screens Does ZVRA Appear In?
So Is Zevra Therapeutics, Inc. (ZVRA) Worth Buying in 2026?
Caution dominates our read on Zevra Therapeutics, Inc. at $11.65. 4 of 6 models see limited upside or outright downside, with the median fair value at $6.60 (-43.3%). Quality at 6.5/10 provides some fundamental cushion. Current holders should re-evaluate their thesis; new buyers should demand a wider margin of safety.
These are quantitative model outputs, not investment recommendations. Zevra Therapeutics, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About ZVRA Stock?
Should I buy ZVRA stock right now?
Based on CirclFi's multi-model analysis, 2 of 6 models see upside for ZVRA at $11.65. The models are divided, which means the investment case depends heavily on your assumptions about Zevra Therapeutics, Inc.'s future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Zevra Therapeutics, Inc.?
Key risks include: limited model coverage (6/13 active), reducing analytical confidence; wide model disagreement (1292% spread), signaling high uncertainty; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.
How does ZVRA compare to its competitors?
Among Biotechnology peers, ZVRA holds a Quality Score of 6.5/10. Comparable companies include ZEOX (QOC 6.6), VIR (QOC 6.5), WVE (QOC 6.6). The relative ranking helps investors identify whether ZVRA offers better fundamental quality than alternatives in the same sector.
Is ZVRA a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. ZVRA's Quality Score of 6.5/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy ZVRA at?
CirclFi does not provide target buy prices or price alerts. However, our 6 active models produce fair value estimates ranging from $0.97 to $13.47. At $11.65, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for ZVRA.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad